Nextcure publishes non-clinical data demonstrating anti-siglec-15 treatment prevented bone loss due to immobilization from acute spinal cord injury

Beltsville, md., dec. 21, 2023 (globe newswire) -- nextcure, inc. (nasdaq: nxtc), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of a manuscript titled “anti-siglec-15 antibody prevents marked bone loss after acute spinal cord injury-induced immobilization in rats” in jmbr plus, a journal of the american society for bone and mineral research (asbmr). the data demonstrated that nc605, a novel anti-siglec-15 (s15) antibody, prevented bone loss, but more importantly preserved bone strength in animal models of severe immobilization resulting from acute spinal cord injury.
NXTC Ratings Summary
NXTC Quant Ranking